|
aap Annual Financial Statements for 2007: Sales +52%, EBIT +36%
2007: Sales EUR28.0 million, EBITDA EUR5.1 million, Net Profit for year EUR1.5 million
Q1/2008: Sales c. EUR8.0 million
aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange and active in biomaterials, fracture healing and joint replacement, achieved in financial year 2007 sales growth of 52% to EUR28.0 million (previous year: EUR18.5 million) and an operating result (EBIT) of EUR3.0 million (+36% on the previous year). Net profit for the year was slightly down by EUR0.1 million to EUR1.5 million (previous year: EUR1.6 million) due to one-off deferred tax expenses with no effect on liquidity. The aap group achieved this growth by means of organic growth in the T&O segment (Sales +26% to EUR7.8 million) and by first-time consolidation of aquired Dutch Fame Medical Group as well as organic growth in the medical biomaterials segment (aap bio implants group, sales +65% to EUR20.2 million), which generated over 70% of overall aap sales in 2007.
| In EUR million | 2007 | 2006 excl. aap NL | Change | | Sales | 28.0 | 18.5 | + 52% | | EBITDA | 5.1 | 3.9 | + 31% | | EBIT | 3.0 | 2.2 | +36% | | EBT | 2.4 | 2.1 | +14% | | net period result | 1.5 | 1.6 | -6% | | Equity (ratio) | 43.4 (64%) | 21.2 (77%) | +101% | | Balance Sheet Total | 68.0 | 27.6 | +143% | | Employees | 289 | 161 | + 80% |
In financial year 2007 the aap group of companies earned a significantly higher EBITDA of EUR5.1 million (previous year: EUR3.9 million).
Group EBIT improved to EUR3.0 million (previous year: EUR2.2 million). EBT amounted to EUR2.4 million and was also up on the previous year’s EUR2.1 million.
With total assets of EUR68.0 million (previous year: EUR27.6 million) the equity ratio was 64%.
According to preliminary calculations aap group sales in the first quarter of 2008 were in the region of EUR8.0 million, or around 35% more than the €5.9 million in the same quarter of the previous year. This organic sales growth year on year resulted from triple-digit percental sales growth by the Trauma & Orthopaedics division due to the delivery of an initial order to a major OEM customer amongst others.
For the financial year 2008 aap anticipates a continuation of this growth trend and aims to achieve organic sales growth of at least 20% and above-average earnings growth.
Publication of the report for the first quarter of 2008 is scheduled for May 14, 2008.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Head of Corporate Communications and Legal Affairs | | Tel.: +49 30 750 19 - 140 | Tel.: +49 30 75019 - 133 | | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
